BioXcel Therapeutics Inc (BTAI) - Gross Profit Margin

BTAI (BioXcel Therapeutics Corp) - company brandmark

Stable raw material supplies ensure the operational reliability of BioXcel Therapeutics. The gross profit margin reflects cost dynamics, where the value of 22.80 represents the most recent figure. Growth is driven by the expansion of the drug Igalmi and AI technologies, although high expenses and regulatory risks threaten the company's financial stability.

BTAI: BioXcel Therapeutics, Inc. Gross Margin 07/04/2022 - 09/19/2026

Comprehensive metric breakdowns and analytics for BioXcel Therapeutics, Inc. (BTAI)

- market price and analyst price targets:
Fundamental valuation:BTAI, BioXcel Therapeutics, Inc.
Signature product of bioxceltherapeutics.com

Gross margin is calculated as the ratio of the difference between revenue and cost of goods sold to total sales, determining direct production efficiency and internal profitability potential. For BioXcel Therapeutics (BTAI), this indicator reflects the economic return from applying AI in drug repositioning, allowing for an assessment of the therapy's commercial viability through the stability of the gross margin.